Wells Fargo’s Inhibrx, Inc. Common Stock INBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14,486
| Closed | -$506K | – | 7783 |
|
|
2024
Q1 | $506K | Sell |
14,486
-9,132
| -39% | -$333K | ﹤0.01% | 3882 |
|
|
2023
Q4 | $897K | Sell |
23,618
-19,547
| -45% | -$419K | ﹤0.01% | 3502 |
|
|
2023
Q3 | $792K | Sell |
43,165
-3,700
| -8% | -$77.4K | ﹤0.01% | 3486 |
|
|
2023
Q2 | $1.22M | Buy |
46,865
+4,141
| +10% | +$96.7K | ﹤0.01% | 3323 |
|
|
2023
Q1 | $806K | Buy |
42,724
+35,264
| +473% | +$820K | ﹤0.01% | 3529 |
|
|
2022
Q4 | $184K | Sell |
7,460
-1,358
| -15% | -$39.9K | ﹤0.01% | 4217 |
|
|
2022
Q3 | $158K | Buy |
8,818
+1,591
| +22% | +$28.7K | ﹤0.01% | 4367 |
|
|
2022
Q2 | $82K | Sell |
7,227
-5,110
| -41% | -$75.2K | ﹤0.01% | 4762 |
|
|
2022
Q1 | $275K | Sell |
12,337
-10,417
| -46% | -$266K | ﹤0.01% | 4800 |
|
|
2021
Q4 | $994K | Sell |
22,754
-6,435
| -22% | -$257K | ﹤0.01% | 4112 |
|
|
2021
Q3 | $972K | Buy |
29,189
+17,692
| +154% | +$538K | ﹤0.01% | 4267 |
|
|
2021
Q2 | $316K | Buy |
11,497
+1,314
| +13% | +$27.4K | ﹤0.01% | 4848 |
|
|
2021
Q1 | $205K | Sell |
10,183
-11,066
| -52% | -$323K | ﹤0.01% | 5140 |
|
|
2020
Q4 | $701K | Buy |
21,249
+14,049
| +195% | +$374K | ﹤0.01% | 4277 |
|
|
2020
Q3 | $130K | Buy |
+7,200
| New | +$130K | ﹤0.01% | 5158 |
|
Other funds holding INBX
Wells Fargo's INBX Position: Q2 2024 in Review
Wells Fargo sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 14,486 shares — an estimated $506K sold.
Wells Fargo first reported a position in INBX in Q3 2020 and held it in 15 quarters. The position peaked at $1.22M in Q2 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.
- Wells Fargo reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 14,486 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $506K.
- Wells Fargo first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 15 quarters.
- Wells Fargo's Inhibrx, Inc. Common Stock position peaked at $1.22M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.